CVRx appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim. Landry’s employment commences on October 12, 2026, with full CFO responsibilities beginning after the filing of the Form 10-Q for the quarter ending September 30, 2026. His compensation includes a $500,000 annual base salary, a target cash incentive equal to 50% of base salary, and equity awards representing 0.80% of outstanding shares. Landry previously served as CFO at Nyxoah SA and Vapotherm Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases.
